APVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States...

Stats
Today's Volume	567 395
Average Volume	266 916
Market Cap	459 683
EPS	$-6.16 ( 2024-04-04 )
Next earnings date	( $-15.65 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00500 (0.74%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Taylor Daphne	Buy	1 584	Common Stock
2024-03-02	Taylor Daphne	Buy	3 667	Common Stock
2024-03-02	Taylor Daphne	Sell	3 667	Restricted Stock Unit
2024-03-04	Taylor Daphne	Sell	1 584	Restricted Stock Unit
2024-03-03	Lamothe Jeffrey G.	Buy	3 667	Common Stock

INSIDER POWER
28.04
Last 99 transactions
Buy: 423 660 \| Sell: 158 934

Volume Correlation

Long: -0.11 (neutral)

Short: -0.16 (neutral)

Signal:(44.908) Neutral

Aptevo Therapeutics Inc Correlation

10 Most Positive Correlations
OPTN	0.913
VERU	0.91
QTEK	0.894
MODV	0.892
GOSS	0.891
HIBB	0.889
NVNO	0.887
TRVN	0.884
FUV	0.884
GROM	0.883

10 Most Negative Correlations
ARNA	-0.944
MLAI	-0.914
PLPC	-0.913
FRBN	-0.912
SLAM	-0.911
VHNA	-0.911
TACT	-0.909
KAII	-0.907
BIOT	-0.907
NCAC	-0.906

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aptevo Therapeutics Inc Correlation - Currency/Commodity

0.57
( weak )

0.69
( moderate )

0.00
( neutral )

0.13
( neutral )

Aptevo Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-567 000 (0.00 %)
EPS:	$-62.62

Q4	2023
Revenue:	$0
Gross Profit:	$-116 000 (0.00 %)
EPS:	$-13.34

Q3	2023
Revenue:	$0
Gross Profit:	$-123 000 (0.00 %)
EPS:	$-22.16

Q2	2023
Revenue:	$0
Gross Profit:	$-150 000 (0.00 %)
EPS:	$-53.95

Financial Reports:

No articles found.

Aptevo Therapeutics Inc

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.